If you have been reading about gastric juice protein and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | About 1419.5 Da | Calculated from the fifteen-residue sequence |
| Residue count | 15 amino acids | Single-letter sequence GEPPPGKPADDAGLV |
| Compound class | Synthetic peptide | Produced by solid-phase synthesis |
| Synonyms | BPC 157; pentadecapeptide BPC 157 | Naming varies across suppliers and papers |
| Appearance | White to off-white powder | Typical form of the lyophilized material |
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
p53, also known as tumor protein p53, TP53, cellular tumor antigen p53 (UniProt name), or transformation-related protein 53 (TRP53) is a regulatory transcription factor protein that is often mutated in human cancers. The p53 proteins (originally thought to be, and often spoken of as, a single protein) are crucial in vertebrates, where they prevent cancer formation. As such, p53 has been described as "the guardian of the genome" because of its role in conserving stability by preventing genome mutation. Hence TP53 is classified as a tumor suppressor gene. The TP53 gene is inactivated in a majority (>50%) of human cancer cases. This can be caused by any various factors, including mutations in the gene, epigenetic events, or interactions with other proteins. This association indicates that the TP53 gene plays a crucial role in preventing cancer formation. TP53 gene encodes proteins that bind to DNA and regulate gene expression to prevent mutations of the genome. In addition to the full-length protein, the human TP53 gene encodes at least 12 protein isoforms. Comparative genomic studies found pathogenic mutations absent in some Neanderthal populations, while modern humans exhibit an expansion of over 1,000 mutated variations. Evidence suggests that the vast majority of these protein-coding variants arose very recently in human history, specifically concentrated within a window of 5,000 to 10,000 years ago.
== Pathophysiology == Myophosphorylase is involved in the breakdown of glycogen to glucose-1-phosphate for use in muscle. The enzyme removes 1,4 glycosyl residues from the outer branches of glycogen and adds inorganic phosphate to form glucose-1-phosphate. Ordinarily, the removal of 1,4 glycosyl residues by myophosphorylase leads to the formation of glucose-1-phosphate during glycogen breakdown and the polar, phosphorylated glucose cannot leave the cell membrane and so is marked for intracellular catabolism. In McArdle's disease, deficiency of myophosphorylase leads to the accumulation of intramuscular glycogen and a lack of glucose-1-phosphate for cellular fuel. Myophosphorylase comes in two forms: form 'a' is phosphorylated by phosphorylase kinase, form 'b' is not phosphorylated. Form 'a' is de-phosphorylated into form 'b' by the enzyme phosphoprotein phosphatase, which is activated by elevated insulin. Both forms have two conformational states: active (R or relaxed) and inactive (T or tense). When either form 'a' or 'b' is in the active state, then the enzyme converts glycogen into glucose-1-phosphate. Myophosphorylase-b is allosterically activated by elevated AMP within the cell, and allosterically inactivated by elevated ATP and/or glucose-6-phosphate. Myophosphorylase-a is active unless allosterically inactivated by elevated glucose within the cell. In this way, myophosphorylase-a is the more active of the two forms as it will continue to convert glycogen into glucose-1-phosphate even with high levels of glycogen-6-phosphate and ATP.
Italian forces entered British Somaliland from Abyssinia on 4 August 1940, overcame the garrison at Hargeisa, and advanced north-east towards the capital Berbera. The British force, including a platoon of 43 Rhodesians in the 2nd Battalion of the Black Watch, took up positions on six hills overlooking the only road towards Berbera and engaged the Italians at the Battle of Tug Argan. Amid heavy fighting, the Italians gradually made gains and by 14 August had almost pocketed the Commonwealth forces. The British retreated to Berbera between 15 and 17 August, the Rhodesians making up the left flank of the rearguard, and by 18 August had evacuated by sea. The Italians took the city and completed their conquest of British Somaliland a day later. No. 237 Squadron embarked on reconnaissance flights and supported ground assaults on Italian desert outposts during July and August 1940. Two British brigades from West Africa arrived to reinforce Kenya's northern frontier in early July—the partly Rhodesian-officered Nigeria Regiment joined the front at Malindi and Garissa, while a battalion of the Gold Coast Regiment, also with Rhodesian commanders attached, relieved the KAR at Wajir. The British forces in East Africa adopted the doctrine of "mobile defence" that was already being used in the Western Desert in North Africa—units embarked on long, constant patrols to guard wells and deny water supplies to the Italians. The British evacuated their north forward position at Buna in September 1940, and expected an attack on Wajir soon after, but the Italians never attempted an assault.
During atrial systole, blood flows from the atria to the ventricles down the pressure gradient. Chordae tendineae are relaxed because the atrioventricular (AV) valves are forced open. When the ventricles of the heart contract in ventricular systole, the increased blood pressures in both chambers push the AV valves to close simultaneously, preventing the backflow of blood into the atria. Since the blood pressure in the atria is much lower than that in the ventricles, the flaps attempt to evert to the low pressure regions. The chordae tendineae prevent this prolapse by becoming tense, which pulls on the flaps, holding them in a closed position.
Sources: en.wikipedia.org
=== Alteration of tRNAs === In some bacteriophages, tRNAs have been assigned to stop codons TAG and TGA to code for amino acids glutamine and tryptophan respectively. The reasons for this codon reassignment are still being studied, it may be related to the infection process. Exposure to outside environmental factors can alter tRNA molecules enough to result in codon reassignment. For example, after being infected with a certain virus, rat liver cells can replace the amino acid selenocysteine with cysteine, a structurally similar amino acid.
Nickel video from the Periodic Videos series (University of Nottingham) Nickel entry (last reviewed October 30, 2019) in the NIOSH Pocket Guide to Chemical Hazards published by the CDC's National Institute for Occupational Safety and Health Toxicological Profile for Nickel (draft for public comment) (PDF) (August 2023) – 422-page report from the United States Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry The metal that brought you cheap flights, BBC News (2015) usgs.gov: Nickel
== Selected publications == Risk assessment of prenatally – induced adverse health effects. (with Neubert, Kavlock, and Klein, eds.), Springer – Verlag, Berlin et al., 1992. Anatomie für Anästhesisten, Blackwell – Wissenschaften, Berlin, 1990, ISBN 978-3894121013 Elektronenmikroskopischer Atlas, Blackwell – Wissenschaft, Berlin, 1989, ISBN 978-3894120542 Anatomie für medizinische Hilfsberufe, Walter de Gruyter, Berlin, 1989. Teratology of the limbs (co-editor), Walter de Gruyter – Verlag, Berlin, 1981. Culture techniques (with Neubert, eds.), Walter de Gruyter– Verlag, Berlin, 1981. Methods in prenatal toxicology (with Neubert and Kwasigroch, eds.), G. Thieme, Stuttgart, 1977.
Sources: en.wikipedia.org
Some anesthetics and chemotherapy drugs are injected intrathecally into the subarachnoid space, where they spread around CSF, meaning substances that cannot cross the blood–brain barrier can still be active throughout the central nervous system. Baricity refers to the density of a substance compared to the density of human cerebrospinal fluid and is used in regional anesthesia to determine the manner in which a particular drug will spread in the intrathecal space. Liquorpheresis is the process of filtering the CSF in order to clear it from endogen or exogen pathogens. It can be achieved by means of fully implantable or extracorporeal devices, though the technique remains experimental today.
GBS colonization of the vagina usually does not cause problems in healthy women; nevertheless, during pregnancy, it can sometimes cause serious illness for the mother and the newborn. GBS is the leading cause of bacterial neonatal infection in the baby during gestation and after delivery, with significant mortality rates in premature infants. GBS infections in the mother can cause chorioamnionitis (a severe infection of the placental tissues) infrequently, postpartum infections (after birth), and it had been related to prematurity and fetal death. GBS urinary tract infections (UTI) may also induce labor and cause premature delivery. In the Western world, GBS (in the absence of effective prevention measures) is the major cause of several bacterial infections of the newborn neonatal infection sepsis, pneumonia, and meningitis, which can lead to death or long-term sequelae. GBS neonatal infection typically originates in the lower reproductive tract of infected mothers. GBS infections in newborns are separated into two clinical syndromes, early-onset disease (EOD) and late-onset disease (LOD). EOD manifests within 0 to 7 days in the newborn, with most cases apparent within 24 h of birth. The most common clinical syndromes of EOD are sepsis without apparent focus, pneumonia, and, less frequently, meningitis. EOD is acquired vertically (vertical transmission), through exposure of the fetus or the baby to GBS from the vagina of a colonized woman, either intrautero or during birth after rupture of membranes.
=== Pharmacokinetics === Tavaborole, when prepared with a 1:1 mixture of ethyl acetate and propylene glycol, has the ability to fully penetrate through the human nail. In studies with cadaver fingernails, a 5% solution of tavaborole penetrated the nail an average of 524.7 mcg/cm2 after two weeks of daily use. Tavaborole is detectable in the blood at a level of 3.54 ng/mL after a single use of 0.2 mL of the 5% solution. Tavaborole has an elimination half-life of 28.5 hours, a maximum concentration of 5.17 ng/mL after two weeks of daily use, and takes 8 days to reach the maximum concentration.
Eating much faster than normal, perhaps in a short space of time Eating until feeling uncomfortably full Eating a large amount even when not hungry Subjective loss of control over how much or what is eaten Planning and allocating specific times for bingeing Eating alone or secretly Not being able to remember what was eaten after the binge Feelings of guilt, shame, or disgust following a food binge Body image disturbance In contrast to bulimia nervosa, binge eating episodes are not regularly followed by activities intended to compensate for the amount of food consumed, such as self-induced vomiting, laxative or enema misuse, or strenuous exercise. BED is characterized more by overeating than dietary restriction. Those with BED often have poor body image and frequently diet, but are unsuccessful due to the severity of their binge eating. Obesity is common in persons with BED, as are depression, low self-esteem, stress and boredom. Regarding cognitive abilities, individuals showing severe binge eating symptoms may experience small dysfunctions in executive functions. Those with BED are also at risk of non-alcoholic fatty liver disease, menstrual irregularities such as amenorrhea, and gastrointestinal problems such as acid reflux and heartburn.
Sources: en.wikipedia.org
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.
The number is an internal laboratory designation from the research group that first described the fragment. It does not encode a molecular weight, a receptor target, or a measured biological effect, and it carries no meaning outside the naming history of the compound.
It contains fifteen amino acid residues and has a calculated mass of roughly 1419.5 daltons. That places it in the short-peptide range, well below the size of small proteins, which affects how it is synthesized, purified, and analyzed.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.